Browsing by Author "Bes, Cemal"

Now showing 1 - 3 of 3

Criteria Sets for Primary Sjogren's Syndrome Are Not Adequate for Those Presenting with Extraglandular Organ Involvements As Their Dominant Clinical Features
(2017) Kabasakal, Yasemin; Kitapcioglu, Gul; Karabulut, Gonca; Tezcan, Mehmet; Balkarli, Ayse; Aksoy, Adem; Yavuz, Aule; Yilmaz, Sema; Kasifoglu, Timucin; Kalyoncu, Umut; Dalkilic, Ediz; Tufan, Abdurrahman; Mercan, Ridvan; Yildiz, Fatih; Senturk, Taskin; Onen, Fatos; Bes, Cemal; Erken, Eren; Tunc, Ercan; Kamali, Sevil; Tarhan, Emine; Yazici, Ayten; Duzgun, Nursen; Bicakcigil, Muge; Yilmaz, Sedat; Ozmen, Mustafa; Ocal, Lale; Alibaz-Oner, Fatma; Solmaz, Dilek; Cobankara, Veli; Nalbant, Selim; Gunal, Esen Kasapoglu; Kaskari, Derya; Goker, Berna; https://orcid.org/0000-0002-0125-8746; 28289872; H-7637-2016
Patients with primary Sjogren's syndrome (pSS) may go undiagnosed or be misclassified due to the insidious nature and wide spectrum of the disease. The available several classification criteria emphasize glandular findings. We aimed to analyze the efficiency of various classification criteria sets in patients diagnosed on the clinical basis by expert opinion and to compare those pSS patients who fulfilled these criteria with those who did not. This is a multicenter study in which 834 patients from 22 university-based rheumatology clinics are included. Diagnosis of pSS was made on the clinical basis by the expert opinion. In this study, we only interviewed patients once and collected available data from the medical records. The European criteria, American-European Consensus Group (AECG) and American College of Rheumatology (ACR) Sjogren's criteria were applied. Majority of the patients were women (F/M was 20/1). The median duration from the first pSS-related symptom to diagnosis was significantly shorter in men (2.5 +/- 2.3 vs 4.3 +/- 5.9 years) (p = 0 < 0.016). When the European, AECG and ACR Sjogren's criteria were applied, 666 patients (79.9%) satisfied at least one of them. In total, 539 patients (64.4%) satisfied the European, 439 (52.6%) satisfied the AECG, and 359 (43%) satisfied the ACR criteria. Among the entire group, 250 patients (29.9%) satisfied all and 168 (20.1%) met none of the criteria. The rates of extraglandular organ involvements were not different between patients who met at least one of the criteria sets and those who met none. There is an urgent need for the modification of the pSS criteria sets to prevent exclusion of patients with extraglandular involvements as the dominant clinical features.
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
(2018) Kimyon, Gezmis; Kiraz, Sedat; Ertenli, Ihsan; Kucuksahin, Orhan; Dalkilic, Ediz; Bes, Cemal; Kanitez, Nilufer Alpay; Kasifoglu, Timucin; Emmungil, Hakan; Coskun, Belkis Nihan; Yagiz, Burcu; Koca, Suleyman Serdar; Cinar, Muhammet; Ates, Askin; Akar, Servet; Bakirli, Duygu Ersozlu; Yazisiz, Veli; Bilge, Nazife Sule Yasar; Tufan, Muge Aydin; Karadag, Omer; Kelesoglu, Ayse Bahar; Mercan, Ridvan; Gercik, Onay; Oz, Burak; Akar, Zeynel Abidin; Yilmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioglu, Ender; Kilic, Levent; Erten, Sukran; Tekgoz, Emre; Tascilar, Koray; Kalyoncu, Umut; https://orcid.org/0000-0003-1537-2192; W-3342-2017
Methodology of a new inflammatory arthritis registry: TReasure
(2018) Tufan, Muge Aydin; Kalyoncu, Umut; Tascilar, Etem Koray; Ertenli, Ali Ihsan; Dalkilic, Huseyin Ediz; Bes, Cemal; Kucuksahin, Orhan; Kasifoglu, Timucin; Alpay Kanitez, Nilufer; Emmungil, Hakan; Kimyon, Gezmis; Yasar Bilge, Nafize Sule; Akar, Servet; Atagunduz, Mehmet Pamir; Koca, Suleyman Serdar; Ates, Askin; Yazisiz, Veli; Terzioglu, Ender; Ersozlu, Emine Duygu; Tufan, Muge Aydin; Cinar, Muhammet; Mercan, Ridvan; Sahin, Ali; Erten, Sukran; Pehlivan, Yavuz; Yilmaz, Sedat; Kelesoglu Dincer, Ayse Bahar; Gercik, Onay; Coskun, Belkis Nihan; Yagiz, Burcu; Kaymaz Tahra, Sema; Aksoy, Aysun; Karadag, Omer; Kilic, Levent; Kiraz, Sedat; 30119164
Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.